Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to better understand how people's mood, behavior, and brains respond to different recreational drugs. We are also trying to understand why some people may feel differently or their brain may respond differently than other people after taking the same recreational drug.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo oral capsule | Placebo Comparator | Participants will receive a placebo at their first or second laboratory visit. |
|
| THC | Experimental | Participants will receive THC (7.5 mg) at their first or second laboratory visit. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo Oral Capsule | Drug | A capsule that contains only dextrose filler administered during the first or second laboratory visit. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Recent Substance Use | Participants will complete the 6-month Timeline Follow-Back (TLFB) and Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory (DFAQ-CU) to assess recent substance use. This measure will capture the frequency of substance use during the past 6 months, with greater values indicating more frequent substance use. | Baseline screening, baseline drug administration, and every 6 months over two years of follow-up |
| CUD/SUD Symptoms | Participants will complete the SCID CUD diagnosis and symptom assessment at baseline screening and yearly follow-ups to evaluate the presence and severity of cannabis use disorder (CUD) and other substance use disorder (SUD) symptoms. | Baseline screening and yearly over the two-year follow-up. |
| Neural Reward Anticipation - fMRI response to reward anticipation (MID) | Participants will complete the Monetary Incentive Delay (MID) task during fMRI scanning to assess neural activation related to reward anticipation. Greater activation in reward-related brain regions (e.g., striatum, prefrontal cortex) indicates greater neural sensitivity to anticipated rewards and the impact of THC on reward processing. | First and second laboratory visits, around 90 minutes to 2 hours after drug administration. |
| Computationally-Derived Behavioral Reward Learning Rate - Learning rate (alpha parameter) | Participants will complete the Bandit task during fMRI scanning. A behavioral measure of learning rate (alpha parameter) will be derived from computational models based on the Rescorla-Wagner (RW) model, with higher learning rates indicating greater learning and adaptation to reward contingencies. | First and second laboratory visits, around 90 minutes to 2 hours after drug administration. |
| Computationally-Derived Behavioral Reward Sensitivity - Reward sensitivity (inverse temperature parameter) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Natania Crane, PhD | Contact | (312) 413-4453 | ncrane3@uic.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Illinois at Chicago | Chicago | Illinois | 60612 | United States |
Demographic, clinical, behavioral, and fMRI data will be collected from 144 adults. All data will be de-identified prior to receipt by the repository, but the information needed to generate a global unique identifier (GUID) for the NIMH Data Archive (NDA) will be collected for each participant.
All data will be deposited to NDA starting 12 months after study begins and will be deposited every six months thereafter following the usual NDA data submission dates until the end of the study.
To request access of the data, researchers will use the standard processes at NDA, and the NDA Data Access Committee will decide which requests to grant. The standard NDA data access process allows access for one year and is renewable.
Not provided
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| ID | Term |
|---|---|
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D013759 | Dronabinol |
| ID | Term |
|---|---|
| D002186 | Cannabinoids |
| D013729 | Terpenes |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| THC | Drug | A capsule that contains 7.5 mg of THC as well as dextrose filler administered during the first or second laboratory visit. |
|
Participants will complete the Bandit task during fMRI scanning, and a behavioral measure of reward sensitivity will be derived from the Rescorla-Wagner (RW) model. Greater values indicate higher sensitivity to rewards and a stronger preference for rewarding outcomes. |
| First and second laboratory visits, around 90 minutes to 2 hours after drug administration. |
| Neural Encoding of Reward Prediction Errors - fMRI response to reward prediction errors (Bandit Task) | Participants will complete the Bandit task during fMRI scanning. fMRI analysis will focus on trial-wise neural encoding of prediction errors, with greater activation indicating more salient reward learning signals in response to prediction errors, reflecting how the brain processes unexpected outcomes during reward learning. | First and second laboratory visits, around 90 minutes to 2 hours after drug administration. |